Twin Vee PowerCats, Co. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Twin Vee PowerCats, Co. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.82M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $14.39M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $33.43M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $31.99M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $15.77M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $11.06M | Mar 31, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.26M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($751.4K) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $3.27M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $10.66M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $6.28M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $4.77M | Mar 31, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.61M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($11.05M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($7.19M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($5.14M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($1.01M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.17M | Mar 31, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.78M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($14.55M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($11.99M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($6.02M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($1.63M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $720.8K | Mar 31, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $586.4K | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.44M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $941.5K | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $211.1K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.50M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $3.10M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $3.73M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $2.76M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.73M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $872.7K | Mar 31, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.88M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($6.97M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($6.93M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($4.15M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($1.95M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $364.6K | Mar 31, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.16M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $6.34M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $5.16M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $3.37M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.94M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $525.2K | Mar 31, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.23M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $25.89M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $39.85M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $38.23M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $20.60M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $4.50M | Mar 31, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.77M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $6.67M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $7.80M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $5.21M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $3.90M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.96M | Mar 31, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.47M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $19.22M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $23.51M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $28.44M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $16.70M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.55M | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $115.6K | Mar 31, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($34.00M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($25.39M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($14.35M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($7.15M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($2.02M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($1.01M) | Mar 31, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.43M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $7.49M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $16.50M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $23.50M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $6.98M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $891.8K | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $215.6K | Mar 31, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $499.9K | Feb 27, 2026 |
| FY2024 | Dec 31, 2024 | $499.9K | Mar 20, 2025 |
| FY2023 | Dec 31, 2023 | $499.9K | Mar 27, 2024 |
| FY2022 | Dec 31, 2022 | $499.9K | Mar 30, 2023 |
| FY2021 | Dec 31, 2021 | $499.9K | Mar 31, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | (11) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | (11) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.24M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 1.49M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 9.52M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | 9.52M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 7.00M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 4.00M | Mar 31, 2022 |